Supernus Pharmaceuticals Inc

SUPN

Market Cap$1.65B

Close$

Compare Supernus Pharmaceuticals

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
Supernus Pharmaceuticals Inc	1253.2	0%	-2%	2.9	-
Market Avg	54.3	1.27%	32%	-	1.3
Healthcare Avg	39.1	1.36%	17%	7.2	1.3

$39.00

Target Price by Analysts

34.7% upsideSupernus Pharmaceuticals Target Price Details

$75.71

Current Fair Value

161.4% upside

Undervalued by 161.4% based on the discounted cash flow analysis.

Share Statistics

Market cap	$1.65 Billion
Enterprise Value	$1.35 Billion
Dividend Yield	$0.0 (0.0%)
Earnings per Share	$0.02
Beta	0.85
Outstanding Shares	54,974,254
Avg 30 Day Volume	390,296

Return

Return on Equity	-
Return on Assets	-
Return on Invested Capital	-

Valuation & Multiples

P/E Ratio	1253.21
PEG	-1262.45
Price to Sales	2.9
Price to Book Ratio	1.81
Enterprise Value to Revenue	2.26
Enterprise Value to EBIT	240.22
Enterprise Value to Net Income	-88
Total Debt to Enterprise	0
Debt to Equity	0

Revenue Sources

No data

ESG Score

No data

About Supernus Pharmaceuticals Inc

CEO: Jack Khattar